Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy

Trial Profile

A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Cardiovascular disorders; Renal failure; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms CREDENCE
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 11 Nov 2019 Results assessing effects of Canagliflozin on cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease were published in the Circulation
    • 09 Nov 2019 Results published in the Janssen Pharmaceuticals Media Release.
    • 09 Nov 2019 According to an Janssen Pharmaceuticals media release, results from the secondary analysis of this study were presented today in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top